Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
| Leidos Holdings, Inc.LDOS · Entity 668 | Director | February 18, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 138,239 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 138,239 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
Leidos Holdings, Inc.
Report date February 18, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,985 |
Ending reported balance
After 2025-02-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-18 · Exercise / conversion · Acquired 4,070 · Balance 19,730 Row 2 · 2025-02-18 · Exercise / conversion · Acquired 3,345 · Balance 23,075 Row 3 · 2025-02-18 · Exercise / conversion · Acquired 2,123 · Balance 25,198 Row 4 · 2025-02-18 · Exercise / conversion · Acquired 1,769 · Balance 26,967 Row 5 · 2025-02-18 · Exercise / conversion · Acquired 2,296 · Balance 29,263 Row 6 · 2025-02-18 · Tax withholding · Disposed 8,278 · Balance 20,985 F1: Represents shares of common stock withheld by the issuer in connection with the option exercise to cover the exercise price and associated fees. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.08 · Expires 2025-05-10 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-18 · Exercise / conversion · Disposed 4,070 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.02 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-18 · Exercise / conversion · Disposed 3,345 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.90 · Expires 2028-05-06 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-18 · Exercise / conversion · Disposed 2,123 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.06 · Expires 2029-05-05 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-18 · Exercise / conversion · Disposed 1,769 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.45 · Expires 2030-05-04 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-02-18 · Exercise / conversion · Disposed 2,296 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld by the issuer in connection with the option exercise to cover the exercise price and associated fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:47 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 25,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001221375-26-000002 · wk-form4_1780606066.xml · derivative · entry 3 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,146 Underlying: Class A Common Stock · 25,146 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001221375-26-000002 · wk-form4_1780606066.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2026. F2 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001221375-26-000002 · wk-form4_1780606066.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000309 · wk-form4_1749087034.xml · derivative · entry 3 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,282 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000309 · wk-form4_1749087034.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2025. F2 · derivative.expiration_date: The RSUs vested on June 2, 2025. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000309 · wk-form4_1749087034.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,296 | $0.00 Strike: $79.45 | $0.00 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · derivative · entry 11 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,296 shares Expires 2030-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,769 | $0.00 Strike: $104.06 | $0.00 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · derivative · entry 10 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,769 shares Expires 2029-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,123 | $0.00 Strike: $103.90 | $0.00 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · derivative · entry 9 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,123 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,345 | $0.00 Strike: $75.02 | $0.00 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · derivative · entry 8 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,345 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,070 | $0.00 Strike: $63.08 | $0.00 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · derivative · entry 7 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,070 shares Expires 2025-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Tax withholdingCommon Stock | 8,278 | $132.26 | $1,094,848.28 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · nonDerivative · entry 6 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,985 F1 · kind: Represents shares of common stock withheld by the issuer in connection with the option exercise to cover the exercise price and associated fees. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionCommon Stock | 2,296 | $79.45 | $182,417.20 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · nonDerivative · entry 5 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionCommon Stock | 1,769 | $104.06 | $184,082.14 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · nonDerivative · entry 4 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionCommon Stock | 2,123 | $103.90 | $220,579.70 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · nonDerivative · entry 3 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionCommon Stock | 3,345 | $75.02 | $250,941.90 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · nonDerivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:32 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionCommon Stock | 4,070 | $63.08 | $256,735.60 |
DisclosureSEC source: 0001628280-25-006392 · wk-form4_1740000735.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:28 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000290 · wk-form4_1718314089.xml · derivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,493 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:46 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000271 · wk-form4_1718153209.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 7, 2024. F2 · derivative.expiration_date: The RSUs vested on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:46 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000271 · wk-form4_1718153209.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2024 Filed May 7, 2024 22:20 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantStock Option (Right to Buy) · Derivative | 1,179 | $0.00 Strike: $142.66 | $0.00 |
DisclosureSEC source: 0001628280-24-021257 · wk-form4_1715120393.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,179 Underlying: Common Stock · 1,179 shares Expires 2031-05-02 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded. Read SEC document |
| May 03, 2024 Filed May 7, 2024 22:20 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 912 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-021257 · wk-form4_1715120393.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,660 Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:15 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,788 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001628280-24-020295 · wk-form4_1714767317.xml · derivative · entry 4 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,788 shares Expires 2024-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:15 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | SaleCommon Stock | 3,014 | $141.97 | $427,909.03 |
DisclosureSEC source: 0001628280-24-020295 · wk-form4_1714767317.xml · nonDerivative · entry 3 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,748 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices from $141.94 to $142.01 inclusive. The reporting person undertakes to providing to Leidos Holdings, Inc., any security holder of Leidos Holdings, Inc., or the staff of the Securities Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the aforementioned range. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:15 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Tax withholdingCommon Stock | 1,774 | $142.19 | $252,245.06 |
DisclosureSEC source: 0001628280-24-020295 · wk-form4_1714767317.xml · nonDerivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,762 F1 · kind: Represents shares of common stock withheld by the issuer in connection with the option exercise to cover the exercise price and associated fees. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:15 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionCommon Stock | 4,788 | $52.70 | $252,327.60 |
DisclosureSEC source: 0001628280-24-020295 · wk-form4_1714767317.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 23:55 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000043 · primary_doc.xml · derivative · entry 3 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:55 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000043 · primary_doc.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 6, 2023. F2 · derivative.expiration_date: The RSUs vested on June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:55 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000043 · primary_doc.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:15 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,193 | $0.00 Strike: $39.70 | $0.00 |
DisclosureSEC source: 0001336920-23-000038 · wf-form4_168418171808359.xml · derivative · entry 3 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,193 shares Expires 2023-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:15 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Tax withholdingCommon Stock | 2,634 | $78.27 | $206,163.18 |
DisclosureSEC source: 0001336920-23-000038 · wf-form4_168418171808359.xml · nonDerivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,748 F1 · kind: Represents shares of common stock withheld by the issuer in connection with the option exercise to cover the exercise price and associated fees. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:15 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | Exercise / conversionCommon Stock | 5,193 | $39.70 | $206,162.10 |
DisclosureSEC source: 0001336920-23-000038 · wf-form4_168418171808359.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2023 Filed May 9, 2023 23:44 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantStock Option (Right to Buy) · Derivative | 2,296 | $0.00 Strike: $79.45 | $0.00 |
DisclosureSEC source: 0001628280-23-016984 · wf-form4_168367582961921.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,296 Underlying: Common Stock · 2,296 shares Expires 2030-05-04 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded. Read SEC document |
| May 05, 2023 Filed May 9, 2023 23:44 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 1,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-016984 · wf-form4_168367582961921.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,189 Read SEC document |
| June 17, 2022 Filed Jun 23, 2022 00:41 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023643 · doc4.xml · derivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:53 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantStock Option (Right to Buy) · Derivative | 1,784 | $0.00 Strike: $104.06 | $0.00 |
DisclosureSEC source: 0001628280-22-013641 · wf-form4_165221594677674.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,784 Underlying: Common Stock · 1,784 shares Expires 2029-05-05 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded. Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:53 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-013641 · wf-form4_165221594677674.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,615 Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:06 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 23,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013947 · doc4.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 23,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on April 1, 2022. F2 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:06 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 23,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013947 · doc4.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:14 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006534 · doc4.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:14 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006534 · doc4.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| May 07, 2021 Filed May 11, 2021 23:53 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantStock Option (Right to Buy) · Derivative | 2,123 | $0.00 Strike: $103.90 | $0.00 |
DisclosureSEC source: 0001628280-21-009872 · wf-form4_162077716889503.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,123 Underlying: Common Stock · 2,123 shares Expires 2028-05-06 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded. Read SEC document |
| May 07, 2021 Filed May 11, 2021 23:53 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 1,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-009872 · wf-form4_162077716889503.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,509 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:40 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 23,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014848 · doc4.xml · derivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,416 Underlying: Class A Common Stock · 23,416 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:00 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006730 · doc4.xml · derivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:00 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 1,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-007582 · wf-form4_158931718053022.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,450 Read SEC document |
| May 10, 2019 Filed May 14, 2019 21:35 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantStock Option (Right to Buy) · Derivative | 3,345 | $0.00 Strike: $75.02 | $0.00 |
DisclosureSEC source: 0001225208-19-007963 · doc4.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345 Underlying: Common Stock · 3,345 shares Expires 2026-05-09 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded. Read SEC document |
| May 10, 2019 Filed May 14, 2019 21:35 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007963 · doc4.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,403 Read SEC document |
| May 11, 2018 Filed May 15, 2018 22:38 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantStock Option (Right to Buy) · Derivative | 4,070 | $0.00 Strike: $63.08 | $0.00 |
DisclosureSEC source: 0001225208-18-009386 · doc4.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070 Underlying: Common Stock · 4,070 shares Expires 2025-05-10 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on or after the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded. Read SEC document |
| May 11, 2018 Filed May 15, 2018 22:38 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009386 · doc4.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,003 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.